Daniel P. van Plew - 09 Feb 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP & General Mgr, Industrial
Signature
/s/**Daniel P. Van Plew
Issuer symbol
REGN
Transactions as of
09 Feb 2024
Net transactions value
-$10,353,341
Form type
4
Filing time
13 Feb 2024, 16:04:28 UTC
Previous filing
12 Dec 2023
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $4,562,635 +12,250 +60% $372.46 32,628 09 Feb 2024 Direct
transaction REGN Common Stock Tax liability $8,184,448 -8,600 -26% $951.68 24,028 09 Feb 2024 Direct
transaction REGN Common Stock Options Exercise $8,819,875 +23,125 +96% $381.40 47,153 09 Feb 2024 Direct
transaction REGN Common Stock Tax liability $15,551,403 -16,341 -35% $951.68 30,812 09 Feb 2024 Direct
holding REGN Common Stock 12,376 09 Feb 2024 2023 GRAT
holding REGN Common Stock 1,084 09 Feb 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -12,250 -50% $0.000000 12,250 09 Feb 2024 Common Stock 12,250 $372.46 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -23,125 -100% $0.000000* 0 09 Feb 2024 Common Stock 23,125 $381.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.